{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:35:16Z","timestamp":1792056916951,"version":"4.4.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T00:00:00Z","timestamp":1688083200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare vasculitis characterized by asthma, systemic manifestations, and blood and tissue eosinophilia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To assess the effectiveness and safety of mepolizumab (anti-IL-5) and benralizumab (anti-IL-5R\u03b1) in EGPA for 24 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a multicenter observational study, including patients with EGPA treated with anti-IL-5\/R\u03b1 biologics in 9 Italian specialized facilities. Systemic disease activity, remission and relapse rate were evaluated from 3 to 24 months after treatment initiation. Respiratory outcomes, hematological parameters, corticosteroid (OCS) and immunosuppressants consumption were also assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>49 patients with relapsing-refractory EGPA were included [26 (53.1%) benralizumab 30mg, 20 (40.8%) mepolizumab 100mg, 3 (6.1%) mepolizumab 300mg]. Overall, 38.8% and 57.1% achieved remission after 12 and 24 months, respectively (69.2% benralizumab and 43.5% mepolizumab). Lower OCS intake and higher blood eosinophil count at baseline were associated with remission at 24 months. Both biologics exerted beneficial effects on severe asthma outcomes. Indeed, 61.2% (61.5% benralizumab and 60.8% mepolizumab) remained exacerbation-free during treatment. Lung function parameters showed improvements in the overall cohort (all <jats:italic>p&amp;lt;<\/jats:italic>0.05), but began to decline from month 12, especially with mepolizumab. Marked reduction in blood eosinophils was registered with mepolizumab (<jats:italic>p&amp;lt;<\/jats:italic>0.0001), while benralizumab depleted both eosinophils (<jats:italic>p&amp;lt;<\/jats:italic>0.0001) and basophils (<jats:italic>p<\/jats:italic>&amp;lt;0.0001). In general, 69.6% (76% benralizumab and 61.9% mepolizumab) of OCS-dependent patients lowered their daily dose by 75%, while 28.3% discontinued these drugs. Immunosuppressants were suspended in 88.2% of cases. Adverse events were reported in 8.2% of patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>These real-world data suggest that anti-IL-5\/R\u03b1 biologics are effective and safe in the long-term as add-on treatments for patients with EGPA.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1204444","type":"journal-article","created":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T19:25:26Z","timestamp":1688153126000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":48,"title":["Effectiveness and safety of anti-IL-5\/R\u03b1 biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study"],"prefix":"10.3389","volume":"14","author":[{"given":"Santi","family":"Nolasco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Portacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Campisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Buonamico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Pelaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alida","family":"Benfante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Triggiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Spadaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Filomena","family":"Caiaffa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Scioscia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Detoraki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Valenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Papia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Tomasello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nunzio","family":"Crimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Scichilone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girolamo","family":"Pelaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna Elisiana","family":"Carpagnano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Crimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,30]]},"reference":[{"key":"B1","first-page":"277","article-title":"Allergic granulomatosis, allergic angiitis, and periarteritis nodosa","volume":"27","author":"Churg","year":"1951","journal-title":"Am J Pathol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2022.103219","article-title":"Eosinophilic granulomatosis with polyangiitis: a review","volume":"22","author":"White","year":"2023","journal-title":"Autoimmun Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/art.41982","article-title":"American College of Rheumatology\/European alliance of associations for rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis","volume":"74","author":"Grayson","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e3181af35a5","article-title":"Cardiac involvement in churg-Strauss syndrome: impact of endomyocarditis: impact of endomyocarditis","volume":"88","author":"Neumann","year":"2009","journal-title":"Med (Baltimore)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000873","article-title":"Therapeutic advances in eosinophilic granulomatosis with polyangiitis","volume":"34","author":"Ford","year":"2022","journal-title":"Curr Opin Rheumatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2015.04.022","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) consensus task force recommendations for evaluation and management","volume":"26","author":"Groh","year":"2015","journal-title":"Eur J Intern Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2017.09.011","article-title":"Long-term systemic corticosteroid exposure: a systematic literature review","volume":"39","author":"Rice","year":"2017","journal-title":"Clin Ther"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-00958-w","article-title":"Evidence-based guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis","author":"Emmi","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12931-021-01775-z","article-title":"Real-life evidence of low-dose mepolizumab efficacy in EGPA: a case series","volume":"22","author":"Detoraki","year":"2021","journal-title":"Respir Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.03.061","article-title":"Mepolizumab in patients with eosinophilic granulomatosis with polyangiitis in remission: what is the right dose","volume":"9","author":"Akdime","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.09.025","article-title":"Mepolizumab 100 mg in severe asthmatic patients with EGPA in remission phase","volume":"9","author":"Caminati","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B13","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/art.41943","article-title":"Mepolizumab for eosinophilic granulomatosis with polyangiitis: a European multicenter observational study","volume":"74","author":"Bettiol","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.jaip.2020.09.054","article-title":"Benralizumab as a steroid-sparing treatment option in eosinophilic granulomatosis with polyangiitis","volume":"9","author":"Guntur","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1016\/j.jaip.2020.05.033","article-title":"Benralizumab as a glucocorticoid-sparing treatment option for severe asthma in eosinophilic granulomatosis with polyangiitis","volume":"8","author":"Padoan","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00451-2020","article-title":"Steroid-sparing effects of benralizumab in patients with eosinophilic granulomatosis with polyangiitis","volume":"6","author":"Nanzer","year":"2020","journal-title":"ERJ Open Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2147\/dddt.s155307","article-title":"Benralizumab in the treatment of severe asthma: design, development and potential place in therapy","volume":"12","author":"Pelaia","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1016\/j.jaip.2021.08.004","article-title":"Benralizumab effectiveness in severe eosinophilic asthma with and without chronic rhinosinusitis with nasal polyps: a real-world multicenter study","volume":"9","author":"Nolasco","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S297273","article-title":"Therapeutic effects of benralizumab assessed in patients with severe eosinophilic asthma: real-life evaluation correlated with allergic and non-allergic phenotype expression","volume":"14","author":"Pelaia","year":"2021","journal-title":"J Asthma Allergy"},{"key":"B21","doi-asserted-by":"publisher","first-page":"637","DOI":"10.12688\/f1000research.24603.2","article-title":"Case report: acute effect of benralizumab on asthma exacerbation without concomitant corticosteroid use","volume":"9","author":"Nolasco","year":"2020","journal-title":"F1000Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9121822","article-title":"Switch from omalizumab to benralizumab in allergic patients with severe eosinophilic asthma: a real-life experience from southern Italy","volume":"9","author":"Pelaia","year":"2021","journal-title":"Biomedicines"},{"key":"B23","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S2213-2600(21)00352-0","article-title":"Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study","volume":"10","author":"Menzies-Gow","year":"2022","journal-title":"Lancet Respir Med"},{"key":"B24","unstructured":"Clinicaltrials.govEfficacy and safety of benralizumab in EGPA compared to mepolizumab"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780330806","article-title":"The American college of rheumatology 1990 criteria for the classification of churg-Strauss syndrome (allergic granulomatosis and angiitis)","volume":"33","author":"Masi","year":"1990","journal-title":"Arthritis Rheumatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treat-492 ment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur Respir J"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.101279","article-title":"Modification and validation of the Birmingham vasculitis activity score (version 3)","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780400222","article-title":"Development and initial validation of the vasculitis damage index for the standardized clinical assessment of damage in the systemic vasculitides","volume":"40","author":"Exley","year":"1997","journal-title":"Arthritis Rheumatol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/MD.0b013e318205a4c6","article-title":"The five-factor score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French vasculitis study group (FVSG) cohort","volume":"90","author":"Guillevin","year":"2011","journal-title":"Med (Baltimore)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.062711","article-title":"EULAR recommendations for conducting clinical studies and\/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis","volume":"66","author":"Hellmich","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"B31","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1164\/rccm.200801-060ST","article-title":"An official American thoracic Society\/European respiratory society statement: asthma control and exacerbations: standardizing endpoints for clin- ical asthma trials and clinical practice: standardizing endpoints for clinical asthma trials and clinical practice","volume":"180","author":"Reddel","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jaci.2003.09.008","article-title":"Development of the asthma control test: a survey for assessing asthma control","volume":"113","author":"Nathan","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2020.106015","article-title":"Comparability of asthma control test scores between self and physician-administered test","volume":"170","author":"Crimi","year":"2020","journal-title":"Respir Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00034805","article-title":"Standardisation of spirometry","volume":"26","author":"Miller","year":"2005","journal-title":"Eur Respir J"},{"key":"B35","unstructured":"IchH\n          European Medicines agency. europa.eu1994"},{"key":"B36","article-title":"Both Th2 and Th17 responses are involved in the pathogenesis of churg-Strauss syndrome","volume":"29","author":"Jakiela","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes171","article-title":"Increased production of IL-5 and dominant Th2-type response in airways of churg-Strauss syndrome patients","volume":"51","author":"Jakiela","year":"2012","journal-title":"Rheumatol (Oxford)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N Engl J Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/cea.13613","article-title":"Real-life evaluation of mepolizumab efficacy in patients with severe eosinophilic asthma, according to atopic trait and allergic phenotype","volume":"50","author":"Pelaia","year":"2020","journal-title":"Clin Exp Allergy"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2020.100462","article-title":"Real-life effectiveness of mepolizumab in patients with severe refractory eosinophilic asthma and multiple comorbidities","volume":"13","author":"Crimi","year":"2020","journal-title":"World Allergy Organ J"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2021.106491","article-title":"Mepolizumab effectiveness in patients with severe eosinophilic asthma and co-presence of bronchiectasis: a real-world retrospective pilot study","volume":"185","author":"Crimi","year":"2021","journal-title":"Respir Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2014.98","article-title":"Eosinophils in vasculitis: characteristics and roles in pathogenesis","volume":"10","author":"Khoury","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00094.2003","article-title":"Effects of eosinophils on nerve cell morphology and development: the role of reactive oxygen species and p38 MAP kinase","volume":"285","author":"Kingham","year":"2003","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.865318","article-title":"Perspectives on the efficacy of benralizumab for treatment of eosinophilic granulomatosis with polyangiitis","volume":"13","author":"Koga","year":"2022","journal-title":"Front Pharmacol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.1016\/j.jaip.2021.06.027","article-title":"FEF25-75% is a more sensitive measure reflecting airway dysfunction in patients with asthma: a comparison study using FEF25-75% and FEV1","volume":"9","author":"Qin","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/j.jaip.2022.02.020","article-title":"Longitudinal impact of sputum inflammatory phenotypes on small airway dysfunction and disease outcomes in asthma","volume":"10","author":"Abdo","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B48","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/nri.2017.90","article-title":"Type 2 immunity in tissue repair and fibrosis","volume":"18","author":"Gieseck RL","year":"2018","journal-title":"Nat Rev Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1204444\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T19:25:30Z","timestamp":1688153130000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1204444\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,30]]},"references-count":48,"alternative-id":["10.3389\/fimmu.2023.1204444"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1204444","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,30]]},"article-number":"1204444"}}